The S3 says there are no immediate plans to offer securities under this shelf. It occurs to me that if management knew of imminent bad news from CD12, they might not be inclined to take an immediate secondary off the table. So although I am reaching a little, I come away with even more confidence in CD12 data than I had before this PR.